While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.